Tag
A 50-year-old woman with metastatic medullary thyroid carcinoma (MTC) lacking RET alterations exhibited a remarkable sustained response to selpercatinib, suggesting potential efficacy beyond RET-mutated cases.
This multicenter study assesses recurrence patterns in medullary thyroid cancer, finding ipsilateral neck sites are the most common recurrence locations, with limited evidence supporting routine contralateral prophylactic central neck disse
Level VII lymph node metastasis in medullary thyroid cancer signifies a highly aggressive phenotype with the poorest prognosis. Reclassifying level VII nodes as N1b improves prognostic accuracy and could refine staging and treatment strateg
This case report details successful management of RET-altered medullary thyroid carcinoma using tarlatamab after selpercatinib progression, highlighting modified dosing to mitigate toxicities and achieve complete response.
A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.
In medullary thyroid carcinoma with biochemical persistent disease after surgery, an early postoperative calcitonin doubling rate of at least 0.3/year strongly identified patients at higher recurrence risk and may help tailor surveillance i
Patient-derived medullary thyroid cancer models preserved tumor heterogeneity, microenvironmental stem-like features, and variable tyrosine kinase inhibitor response, supporting more personalized preclinical testing.
This systematic review and meta-analysis suggests that thyroid lobectomy may offer comparable oncologic outcomes to total thyroidectomy for selected patients with sporadic medullary thyroid cancer, while significantly reducing postoperative
A multicenter Chinese cohort of 509 initially treated MTC patients identifies new preoperative basal calcitonin thresholds (241.9, 693.9, 2378.5, 2787.1 pg/mL) that better predict central, ipsilateral lateral, bilateral/contralateral latera
A multicenter Chinese cohort identifies new preoperative basal calcitonin thresholds (241.9, 693.9, 2378.5, 2787.1 pg/mL) that stratify risk of central, ipsilateral lateral, bilateral/contralateral lateral, and upper mediastinal lymph node
